Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006

Morbidity and Mortality Weekly Report

Volumn 56, Issue 7, 2007, Pages 137-141

  Cheng, S ^a   Abramova, L ^a   Saab, G ^b   Turabelidze, G ^c   Patel, P ^d   Arduino, M ^d   Hess, T ^d   Kallen, A ^e   Jhung, M ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Missouri   (United States)

^c MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; COMORBIDITY; FEMALE; FIBROSIS; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SKIN DISEASE; UNITED STATES;

CASE-CONTROL STUDIES; COMORBIDITY; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MISSOURI; RENAL DIALYSIS; RISK FACTORS; SKIN DISEASES;

EID: 33847248060     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
2. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-90.
3. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-6.
4. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003;143:678-81.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
6. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006;145:234-5.
7. Food and Drug Administration. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm.
8. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205-13.
9. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
10. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiologica 2001;42:339-41.